| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/19/2004 | WO2003086306A3 5ht2c receptor modulators |
| 02/19/2004 | WO2003082190A3 Spirocyclic amides as cannabinoid receptor modulators |
| 02/19/2004 | WO2003080640B1 Lymphatic and blood endothelial cell genes |
| 02/19/2004 | WO2003070188A3 Method of treating trx mediated diseases |
| 02/19/2004 | WO2003065989A3 (oxime)carbamoyl fatty acid amide hydrolase inhibitors |
| 02/19/2004 | WO2003065988A3 A combination for treating cold and cough |
| 02/19/2004 | WO2003065987A3 Granzyme b inhibitors |
| 02/19/2004 | WO2003065046A3 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
| 02/19/2004 | WO2003049593A3 Prevention of flap necrosis in plastic surgery |
| 02/19/2004 | WO2003045974A3 Methods and compositions for derepression of iap-inhibited caspase |
| 02/19/2004 | WO2003043639A3 PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER |
| 02/19/2004 | WO2003043615A3 Hypertonia treatment during the acute phase of a cerebrovascular accident |
| 02/19/2004 | WO2003037168A3 Methods and formulations for minimizing spasticity in blood vessel grafts |
| 02/19/2004 | WO2003034028A3 Methods for identifying and using modulators of estrogen related receptor gamma |
| 02/19/2004 | WO2003024402A3 Lpa receptor agonists and antagonists and methods of use |
| 02/19/2004 | WO2003014731A3 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 02/19/2004 | WO2002066498A3 Peptide inhibiting platelet derived growth factor (pdgf-bb) and fibroblast growth factor (bfgf) activity |
| 02/19/2004 | WO2002065985A3 Methods of treating diabetes mellitus |
| 02/19/2004 | WO2002064160A3 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 02/19/2004 | WO2002061086A3 Human leucine-rich repeat containing protein expressed predominately in small intestine, hlrrsi1 |
| 02/19/2004 | WO2002048337A3 Secreted human proteins |
| 02/19/2004 | WO2002042328A3 Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon |
| 02/19/2004 | WO2002024214A3 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 02/19/2004 | US20040034237 Materials and methods for the treatment of hypertension and angina |
| 02/19/2004 | US20040034231 Amidinophenyl-4-aminoacetic acid derivative is useful for treating diseases such as thrombosis, apoplexy, cardiac infarction, inflammation and arteriosclerosis, which are associated with coagulation factors xa, IXa and thrombin |
| 02/19/2004 | US20040034229 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists |
| 02/19/2004 | US20040034218 Farnesyl transferase inhibiting benzoheterocyclic derivatives |
| 02/19/2004 | US20040034216 A gonane ring or with the nitrogen forming a heterocyclic structure; antiinflammation agents, antitumor agents; treating asthma, allergic disease, chronic obstructive pulmonary disease, atopic dermatitis, AIDS, arrhythmias |
| 02/19/2004 | US20040034090 Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors |
| 02/19/2004 | US20040034084 Side effect reduction; for treatment of AIDS, cancer and arthritis |
| 02/19/2004 | US20040034076 Such as methyl-3-azido-2-((4,6-dimethoxy-2-pyrimidinyl)oxy) 3,3-diphenylpropionate; for treatment of high blood pressure |
| 02/19/2004 | US20040034073 Analgesic agents, modulating the activity of a cannabinoid receptor, treating hypertension, inflammation, pain, autoimmune diseases, allergic diseases, glaucoma, multiple sclerosis, Huntington's chorea, spinal chord injury |
| 02/19/2004 | US20040034072 Aza-amino acid derivatives (factor Xa inhibitors 15) |
| 02/19/2004 | US20040034066 Rosiglitazone hydrochloride is stable, water solubility, high melting point, bulk flow and good for bulk preparation and handling; salt formation |
| 02/19/2004 | US20040034065 A mixture of valsartan, an insulin secretion enhancer or a insulin sensitizer, for treating hypertension, congestive heart failure, diabetes, type 2 diabetes, renal failure, premenstrual syndrome, coronary heart disease |
| 02/19/2004 | US20040034061 An antagonist of corticotropin releasing factor receptor, treating depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disorders, drug dependence |
| 02/19/2004 | US20040034057 Salt formation by dissolving donepezil in ethanol, adding hydrogen chloride, forming polymorphic crystal |
| 02/19/2004 | US20040034055 For treating central nervous system disorders, immunomodulatory disorders, antimalaria, viral disease of Borna virus, Hepatitis; a 6-azatricyclo(6.3.1.01,6)dodecane derivatives |
| 02/19/2004 | US20040034052 Antitumor agents |
| 02/19/2004 | US20040034046 Quinazoline derivatives |
| 02/19/2004 | US20040034043 Positively-charged peptide nucleic acid analogs with improved properties |
| 02/19/2004 | US20040034040 E.g., 5-(4-(3-chloro-4-methoxybenzylamino)-5,6,7,8-tetra-hydro-1-benzothieno(2,3 -d) pyrimidin-2-yl)valeric acid to treat high pullmonary pressure; hypotensive agents; liver, cardiovascular, kidney and sexual disorders; antiallergens |
| 02/19/2004 | US20040034037 Heteroaryl compounds useful as inhibitors of GSK-3 |
| 02/19/2004 | US20040034035 Calcium channel inhibitors comprising benzhydril spaced from piperazine |
| 02/19/2004 | US20040034034 Novel piperazine derivatives |
| 02/19/2004 | US20040034031 3,4-Disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines |
| 02/19/2004 | US20040034028 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors |
| 02/19/2004 | US20040034026 The use of a vasculostatic compound and a second active ingredient which decreases the activity of the epidermal growth factor (EGF); synergistic, angiogenesis inhibitors; antiproliferative agents; tyrosine kinase enzyme inhibitors |
| 02/19/2004 | US20040034022 Polymorphic forms/hydrates of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride |
| 02/19/2004 | US20040034020 A purine deriveative, useful for treatment of inflammatory conditions, immune disorders, tissue injury, infections, and cancer |
| 02/19/2004 | US20040034017 4-fluoroalkyl-2h-benzopyrans anti-estogenic activity |
| 02/19/2004 | US20040034012 Superior arginine vasopressin receptor antagonism; a 6-membered aromatic ring having nitrogen at the 2-position there of is substituted at 2 position of the imidazobenzazepine ring |
| 02/19/2004 | US20040034008 N-alkylpiperdino-4-yl-urea-pyrazole derivative for treating obesity, metabolic disorders, eating disorders and diabetes |
| 02/19/2004 | US20040034005 Administering to a patient suffering from psychological disoders a (1,4)diazocino(7,7,1-hi)inodle derivative as 5HT2c agonist or partial agonist |
| 02/19/2004 | US20040034001 Administering to the female patient undergoing hormone replacement therapy, an effective amounts of drospirenone (DRSP) and at least one estrogen to reduce the blood pressure |
| 02/19/2004 | US20040033995 Nitrogen compounds, stereoisomers and/or racemic mixtures used as enzyme inhibitors for prophylaxis of inflammatory diseases |
| 02/19/2004 | US20040033994 Use of compounds comprising a nitrogen-oxygen heterocycle |
| 02/19/2004 | US20040033993 Treatment of cardiovascular and related pathologies |
| 02/19/2004 | US20040033992 Treatment of cardiovascular and related pathologies |
| 02/19/2004 | US20040033991 Treating of cardiovascular and related pathologies |
| 02/19/2004 | US20040033990 Administering mixtures of heterocyclic imines, calcium channel blockers, adrenergic blocking agents, anticoagulants, diuretics and angiotensin converting enzyme inhibitors, for prophylaxis of heart diseases such as arrhythmias or necrosis |
| 02/19/2004 | US20040033989 Treatment of cardiovascular and related pathologies |
| 02/19/2004 | US20040033965 Method for treating obesity |
| 02/19/2004 | US20040033964 For treating atheroma, tumors and other neoplastic tissue; treating atherosclerotic inflammation |
| 02/19/2004 | US20040033952 Modified mature insulin variants and composition containing same |
| 02/19/2004 | US20040033951 Modified mature insulin variants and composition containing same |
| 02/19/2004 | US20040033946 Cell damage inhibitor |
| 02/19/2004 | US20040033937 Reduction of the electrocardiographic ot interval |
| 02/19/2004 | US20040033936 Reduced or "leuco" forms produced and/or stabilised by mixing the unreduced compounds or the reduced compounds, respectively, with acid and a sulphydryl compound, especially a sulphur-containing amino acid, or peptide or derivative |
| 02/19/2004 | US20040033517 Compositions and methods relating to endothelial cell signaling using the protease activated receptor (PAR1) |
| 02/19/2004 | US20040033491 Proteins and nucleic acids encoding same |
| 02/19/2004 | US20040033267 Nanoparticulate compositions of angiogenesis inhibitors |
| 02/19/2004 | US20040033258 Compression molded blend of a basic medicinal component having an unpleasant taste, a saccharide, a polyanionic polymer, a corrigent, and carboxymethylcellulose; quickly disintegrating in the oral cavity. |
| 02/19/2004 | US20040033202 Nanoparticulate sterol formulations and novel sterol combinations |
| 02/19/2004 | US20040033200 Modified FVII in treatment of ARDS |
| 02/19/2004 | CA2497658A1 Chromone derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | CA2495518A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | CA2495516A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | CA2495502A1 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | CA2495493A1 Cereal based food product comprising dha and/or epa |
| 02/19/2004 | CA2495489A1 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer |
| 02/19/2004 | CA2495293A1 Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | CA2495085A1 Diagnosis and treatment of tuberous sclerosis |
| 02/19/2004 | CA2495071A1 Isosorbide mononitrate compositions and methods of their use |
| 02/19/2004 | CA2495067A1 Mcp-1 receptor antagonists and method of use thereof |
| 02/19/2004 | CA2494916A1 Medicinal composition for lowering blood lipid level |
| 02/19/2004 | CA2494865A1 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | CA2494827A1 Cannabinoid receptor ligands |
| 02/19/2004 | CA2494785A1 Dihydropyrazolopyridine compounds |
| 02/19/2004 | CA2494298A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| 02/19/2004 | CA2494028A1 Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors |
| 02/19/2004 | CA2494026A1 Phosphodiesterase 4 inhibitors |
| 02/19/2004 | CA2494014A1 Monocyclic derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | CA2493660A1 Process for preparing quinolin antibiotic intermediates |
| 02/19/2004 | CA2493625A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/19/2004 | CA2493008A1 Aryl and heteroaryl compounds and methods to modulate coagulation |
| 02/19/2004 | CA2492837A1 Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications |
| 02/18/2004 | EP1389619A1 Pkb-3564 substance with neovascularization inhibitory activity |
| 02/18/2004 | EP1389618A1 Pyrazolo 1,5-a]pyridines and medicines containing the same |
| 02/18/2004 | EP1389611A1 20-hydroxyeicosatetraenoic acid production inhibitors |